An interesting opinion piece has appeared on Medtechinsider about the role of “start-ups” in bringing innovative technology to market, and more particularly the role of the bigger players in the commercialisation process. The article can be found here and discusses the challenges inherent in the current commercialisation of new disruptive technologies, namely that small companies can’t afford to go it alone, large companies are putting risky projects on hold, so the answer may lie in the latter staying very close to the former. It’s worth a read for the actively interested clinician, because so many new technologies of the future will come from the clinical coalface and it’s important to understand the lie of the land before embarking on a pet project.
Source: Medtechinsider
published: February 15, 2012 in: medlatest Editorial, Technology